France
· Delayed Price · Currency is EUR Neovacs Statistics
Total Valuation
Neovacs has a market cap or net worth of EUR 7,450. The enterprise value is -197,630.
| Market Cap | 7,450 |
| Enterprise Value | -197,630 |
Important Dates
The last earnings date was Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Neovacs has 2.07 million shares outstanding.
| Current Share Class | 2.07M |
| Shares Outstanding | 2.07M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.02 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.01 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.05 |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.01.
| Current Ratio | 0.64 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.39% and return on invested capital (ROIC) is -12.21%.
| Return on Equity (ROE) | -98.39% |
| Return on Assets (ROA) | -11.09% |
| Return on Invested Capital (ROIC) | -12.21% |
| Return on Capital Employed (ROCE) | -36.33% |
| Revenue Per Employee | 21,697 |
| Profits Per Employee | -1.65M |
| Employee Count | 22 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -100.00% in the last 52 weeks. The beta is -167.20, so Neovacs's price volatility has been lower than the market average.
| Beta (5Y) | -167.20 |
| 52-Week Price Change | -100.00% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 28.60 |
| Average Volume (20 Days) | 18,744,476 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neovacs had revenue of EUR 433,937 and -32.91 million in losses. Loss per share was -188.61.
| Revenue | 433,937 |
| Gross Profit | -2.77M |
| Operating Income | -6.62M |
| Pretax Income | -33.95M |
| Net Income | -32.91M |
| EBITDA | -6.43M |
| EBIT | -6.62M |
| Loss Per Share | -188.61 |
Balance Sheet
The company has 435,449 in cash and 230,367 in debt, giving a net cash position of 205,082 or 0.10 per share.
| Cash & Cash Equivalents | 435,449 |
| Total Debt | 230,367 |
| Net Cash | 205,082 |
| Net Cash Per Share | 0.10 |
| Equity (Book Value) | 18.06M |
| Book Value Per Share | 103.50 |
| Working Capital | -1.37M |
Cash Flow
In the last 12 months, operating cash flow was -3.60 million and capital expenditures -79,706, giving a free cash flow of -3.68 million.
| Operating Cash Flow | -3.60M |
| Capital Expenditures | -79,706 |
| Free Cash Flow | -3.68M |
| FCF Per Share | -1.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,525.96% |
| Pretax Margin | -7,823.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neovacs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -441,804.15% |
| FCF Yield | -49,408.40% |
Stock Splits
The last stock split was on December 5, 2024. It was a reverse split with a ratio of 0.0001.
| Last Split Date | Dec 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0001 |
Scores
Neovacs has an Altman Z-Score of -4.84. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.84 |
| Piotroski F-Score | n/a |